Sep 2, 2015 ... limited to one such submission for all plaintiffs and one such ..... ARMSTRONG, ET AL. v. .... Pharmaceuticals, Inc., Janssen Research & Development, LLC, ... Meunier and Leonard A. Davis are well qualified to carry out the ...


Oct 12, 2016 ... ... Allen v. Janssen Pharmaceuticals, Inc., et al., Case No. 3:15- ... Janssen Research & Development LLC, No. ..... 1:16-cv-08838: Joy Davis vs.


MorphoSys AG v. Janssen Biotech Inc. et al, No. 1:2016cv00221 - Document 471 (D. Del. 2019) case opinion from the District of Delaware US Federal District ...


... of America et al v. Janssen Pharmaceutical N.V. et al, case number 2:16-cv- 06997, from California Central Court. ... Janssen Research and Development, LLC ...


Dec 7, 2016 ... Invokana and its sister drug Invokamet belong to a class of. 2 diabetes drugs .... DAVIS v. JANSSEN PHARMACEUTICALS, INC., C.A. No. 1:16-08838 ... JANSSEN RESEARCH & DEVELOPMENT LLC, ET AL., C.A. No. 3:16- ...


JANSSEN PHARMACEUTICALS INC JOHNSON JOHNSON JANSSEN ... Johnson, and Janssen Research & Development, LLC (collectively referred to herein as ... All of the cases in this mass tort action consist of male plaintiffs who allege they ...... 682, 42 U.S.C. § 201 et seq. and was approved or licensed; or is generally ...


and Janssen Research & Development, LLC,1 have taken cross-appeals from the judgment ... All of the cases in this mass tort involve male plaintiffs who allege they developed ..... Kurer v. Parke, Davis & Co., 679 N.W.2d 867, 876 (Wis.


American Tradition Partnership, Inc., et al v. ..... Dart Cherokee Basin Operating Co., LLC v. Owens · Davis v. Int'l Union, UAAAIWA ... Ortho-McNeil-Janssen Pharmaceuticals v. ... v. Laborers District Council Construction Industry Pension Fund.


Hugh M. Davis,e Walter Reinisch,f Brian G. Feagan,g Paul Rutgeerts,h ... Translational Medicine Sciences, Janssen Research & Development, LLC, Spring House, PA, USA dDepartment of Clinical ... Background and Aims: To assess golimumab pharmacokinetics [PK] and exposure-response [ER] .... 36. O. Adedokun et al.